Oscar Health’s second quarter saw results well above Wall Street’s expectations, yet the market response was notably negative. Management credited disciplined pricing, technology-driven cost efficiencies, and strong execution in the individual health insurance market for driving year-over-year revenue and margin improvement. CEO Mark Bertolini highlighted that “disciplined pricing, differentiated consumer products and a scalable technology platform” fueled growth, with membership up 46% and administrative cost ratios reaching historic lows. The company cited favorable medical utilization and risk adjustment dynamics as further contributors to the positive results.
Is now the time to buy OSCR? Find out in our full research report (it’s free for active Edge members).
Oscar Health (OSCR) Q2 CY2026 Highlights:
- Revenue: $4.88 billion vs analyst estimates of $4.74 billion (70.4% year-on-year growth, 2.9% beat)
- Adjusted EPS: $1.10 vs analyst estimates of $0.38 (significant beat)
- Adjusted EBITDA: $415.3 million vs analyst estimates of $170.9 million (8.5% margin, significant beat)
- Operating Margin: 8%, up from -8% in the same quarter last year
- Market Capitalization: $9.13 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Oscar Health’s Q2 Earnings Call
- Andrew Mok (Barclays) asked about outpatient utilization trends and the pace for the rest of the year. CEO Mark Bertolini explained that while outpatient was slightly elevated, overall trends were stable and utilization remained in line with expectations.
- Jessica Tassan (Piper Sandler) questioned Oscar’s visibility into utilization and MLR guidance despite higher deductibles. Bertolini responded that stable risk profiles and real-time data tracking gave management confidence in their projections.
- Parker Snure (Raymond James) inquired about rate positioning and ACA market enrollment for 2027. Bertolini said the market remains rational, with Oscar prepared to adjust pricing and product offerings if regulations change.
- Raj Kumar (Stephens Inc.) asked about the recent ICHRAx partnership and capabilities. Bertolini described ICHRAx as enabling lower-cost administration and broader network access, with all major competitors participating on the platform.
- Justin Lake (Wolfe Research) pressed for details about the financial impact of CMS eligibility reviews on member disenrollment. Bertolini said the company has established reserves for at-risk members, and CFO Richard Blackley confirmed this risk is factored into guidance.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will closely watch (1) the impact of CMS eligibility reviews on churn and membership stability, (2) the scaling of AI-powered tools for claims and care navigation, and (3) the adoption and profitability of the ICHRAx platform targeting small businesses and gig workers. Execution on product innovation and operational efficiency will also be key for sustained margin improvement.
Oscar Health currently trades at $29.44, down from $30.11 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
